Technical Analysis for IONS - Ionis Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 39.94 | -2.06% | -0.84 |
Earnings due: May 4
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Historical IONS trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
New 52 Week Low | Weakness | 0.00% | |
Multiple of Ten Bearish | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
New 52 Week Closing Low | Bearish | -2.06% | |
New 52 Week Low | Weakness | -2.06% | |
Wide Bands | Range Expansion | -2.06% | |
Oversold Stochastic | Weakness | -2.06% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Down 3% | about 15 hours ago |
60 Minute Opening Range Breakdown | about 17 hours ago |
Down 2 % | about 17 hours ago |
Fell Below Previous Day's Low | about 17 hours ago |
New 52 Week Low | about 17 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/04/2021
Ionis Pharmaceuticals, Inc. Description
Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. It markets KYNAMRO for the treatment of homozygous familial hypercholesterolemia. The company's drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; IONIS-TTRRx, a drug for the treatment of patients with various forms of TTR amyloidosis, including familial amyloid polyneuropathy, familial amyloid cardiomyopathy, and wild-type TTR amyloidosis; and nusinersen, a drug for the treatment of infants and children with spinal muscular atrophy. It is also developing Custirsen, which is in two Phase III studies to treat cancer; and Plazomicin that is Phase III study for the treatment of severe bacterial infection. In addition, the company is developing products, which are Phase II clinical trials include IONIS-DMPK-2.5Rx for myotonic dystrophy type 1; IONIS-HTTR for huntington's disease; ATL1103 for acromegaly; IONIS-FXIRx (BAY 2306001) for clotting disorders; IONIS-APO(a)-LRx for high Lp; IONIS-ANGPTL3-LRx for mixed dyslipidemias; Apatorsen (OGX-427) and IONIS-STAT3-2.5Rx (AZD9150) for cancers; EXC 001 (PF-06473871) for scarring; ATL1102 for multiple sclerosis; and RG-101 for hepatitis C virus infection, as well as products for the treatment of diabetes and obesity. Further, its products in Phase I clinical include IONIS-GCCRRx for cushing's syndrome; IONIS-PKKRx for hereditary angioedema; RG-012 for alport syndrome; IONIS-AR-2.5Rx (AZD5312) for prostate cancer; IONIS-HBVRx for hepatitis B virus infection; IONIS-GSK4-LRx for ocular disease; and IONIS-DGAT2Rx for nonalcoholic steatohepatitis. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Organ Systems Alcohol Diabetes Cancers Rare Diseases Drug Discovery Genetics Prostate Cancer Disorders Lipid Neurological Disorders Hepatitis B Multiple Sclerosis Obesity Dystrophy Cholesterol Steatohepatitis Hepatitis C Amyloid Hepatitis B Virus Hepatitis C Virus Huntington's Disease Myopathy Amyloidosis Angioedema Hereditary Angioedema Spinal Muscular Atrophy Treatment Of Diabetes Cardiomyopathy Dyslipidemia Hypercholesterolemia Acromegaly Cushing's Syndrome Myotonic Dystrophy Orphan Drugs Therapeutic Gene Modulation Antisense RNA Familial Amyloid Polyneuropathy Hepatitis C Virus Infection Mozy Ocular Disease Polyneuropathy Severe And Rare Diseases Apatorsen Hepatitis B Virus Infection Homozygous Familial Hypercholesterolemia Ionis Lipodystrophy Mixed Dyslipidemia Onemia TTR Amyloidosis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 64.37 |
52 Week Low | 39.18 |
Average Volume | 1,302,283 |
200-Day Moving Average | 52.99 |
50-Day Moving Average | 50.58 |
20-Day Moving Average | 43.80 |
10-Day Moving Average | 42.15 |
Average True Range | 1.99 |
ADX | 30.48 |
+DI | 18.14 |
-DI | 40.30 |
Chandelier Exit (Long, 3 ATRs ) | 50.00 |
Chandelier Exit (Short, 3 ATRs ) | 45.14 |
Upper Bollinger Band | 50.49 |
Lower Bollinger Band | 37.11 |
Percent B (%b) | 0.21 |
BandWidth | 30.56 |
MACD Line | -2.94 |
MACD Signal Line | -2.86 |
MACD Histogram | -0.0818 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 42.55 | ||||
Resistance 3 (R3) | 42.59 | 41.75 | 42.12 | ||
Resistance 2 (R2) | 41.75 | 41.09 | 41.74 | 41.97 | |
Resistance 1 (R1) | 40.85 | 40.68 | 40.43 | 40.81 | 41.82 |
Pivot Point | 40.01 | 40.01 | 39.81 | 40.00 | 40.01 |
Support 1 (S1) | 39.11 | 39.35 | 38.69 | 39.07 | 38.06 |
Support 2 (S2) | 38.27 | 38.94 | 38.26 | 37.91 | |
Support 3 (S3) | 37.37 | 38.27 | 37.77 | ||
Support 4 (S4) | 37.33 |